Market Cap 451.38B
Revenue (ttm) 61.16B
Net Income (ttm) 4.23B
EPS (ttm) N/A
PE Ratio 23.75
Forward PE 18.36
Profit Margin 6.91%
Debt to Equity Ratio -12.03
Volume 4,314,900
Avg Vol 6,863,834
Day's Range N/A - N/A
Shares Out 1.77B
Stochastic %K 21%
Beta 0.30
Analysts Strong Sell
Price Target $276.37

Company Profile

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 847 932 7900
Address:
1 North Waukegan Road, North Chicago, United States
Diviend__dollar
Diviend__dollar Aug. 31 at 9:29 PM
Investing $10,000 in EACH of these names would pay the following annual dividends $AVGO $70 $ABBV $270 $JNJ $202 $LLY $60 $SCHD $301 Here is the 5 Year Growth for each of these as well $AVGO 13% $ABBV 6% $JNJ 5% $LLY 15% $SCHD 8%
0 · Reply
p3akyblinder
p3akyblinder Aug. 31 at 8:56 PM
$MLTX Talk about perfect timing for my last post... the appointment of Liz Gutierrez as U.S. President was just announced on LinkedIn. "I'm thrilled to begin a new chapter as President, U.S. at MoonLake Immunotherapeutics. The opportunity to help build the U.S. organization at such an exciting point in the company's evolution is incredibly energizing. Since joining, I've been struck not only by the caliber of talent across the organization, but also by the culture. There is a strong sense of purpose, openness, and shared commitment to making a difference for patients that makes MoonLake a truly special place to be." MoonLake will be acquired and operated as a wholly-owned subsidiary of $LLY , $ABBV , $MRK, or $NVS . You heard it here first.
1 · Reply
LT_Smash
LT_Smash Aug. 31 at 7:56 PM
0 · Reply
Stocktwits
Stocktwits Aug. 31 at 7:40 PM
$ABBV chart courtesy of @JFDI
0 · Reply
ilcail
ilcail Aug. 31 at 7:20 PM
$SLS 009 (2nd drug) design to work in combo with approved Venetoclax from $ABBV. Ven is a BCL-2 inhibitor. A main escape hatch is MCL-1, which can be stared by CDK9 inhibition... by SLS009. Sellas’s thesis: aza/ven + SLS009 hits both anti-apoptotic arms.
2 · Reply
JFDI
JFDI Aug. 31 at 7:07 PM
$ABBV off the 10wk SMA
0 · Reply
nlrmandate
nlrmandate Aug. 31 at 6:06 PM
$VKTX Hey $ABBV $NVO $AZN ..... Viking is the ONLY clinical biotech with a pipeline capable of competing with $LLY within 12-18 months. Buy or partner with Viking NOW or be prepared for $LLY to own the freakin world in a few years!!
1 · Reply
WallStJesus
WallStJesus Aug. 31 at 6:04 PM
$ABBV REPEAT MARCH BUYER
0 · Reply
nlrmandate
nlrmandate Aug. 31 at 3:26 PM
$VKTX Hey $ABBV $NVO ..... Viking is the ONLY clinical biotech with a pipeline capable of competing with LLY within 18 months. BO or partner with Viking NOW or LLY will own the freakin world in a few years!!
0 · Reply
focafoca99
focafoca99 Aug. 31 at 3:12 PM
$ABBV set to appear at the Wells Fargo 21st Annual Healthcare Conference on Sep 9, 2026. https://www.rapidticker.com/news/abbv-abbvie-to-present-at-the-09b424
0 · Reply
Latest News on ABBV
AbbVie submits Skyrizi application to the EMA

2026-08-27T09:21:03.000Z - 4 days ago

AbbVie submits Skyrizi application to the EMA


AbbVie price target raised to $303 from $298 at Piper Sandler

2026-08-20T10:55:24.000Z - 11 days ago

AbbVie price target raised to $303 from $298 at Piper Sandler


AbbVie price target raised to $300 from $295 at Wells Fargo

2026-08-17T10:55:57.000Z - 14 days ago

AbbVie price target raised to $300 from $295 at Wells Fargo


AbbVie price target raised to $260 from $246 at Evercore ISI

2026-08-10T12:16:02.000Z - 21 days ago

AbbVie price target raised to $260 from $246 at Evercore ISI


AbbVie upgraded to Buy from Hold at Erste Group

2026-08-05T14:36:14.000Z - 26 days ago

AbbVie upgraded to Buy from Hold at Erste Group


AbbVie price target raised to $288 from $261 at Guggenheim

2026-08-04T10:52:04.000Z - 27 days ago

AbbVie price target raised to $288 from $261 at Guggenheim


AbbVie price target raised to $290 from $282 at Canaccord

2026-08-03T11:06:04.000Z - 4 weeks ago

AbbVie price target raised to $290 from $282 at Canaccord


AbbVie says ‘quite pleased’ with Skyrizi momentum

2026-07-31T14:01:14.000Z - 4 weeks ago

AbbVie says ‘quite pleased’ with Skyrizi momentum


AbbVie sees Q3 adjusted EPS $3.84-$3.88, consensus $3.84

2026-07-31T13:30:48.000Z - 4 weeks ago

AbbVie sees Q3 adjusted EPS $3.84-$3.88, consensus $3.84


AbbVie Earnings Call Transcript: Q2 2026

Jul 31, 2026, 9:00 AM EDT - 4 weeks ago

AbbVie Earnings Call Transcript: Q2 2026


AbbVie Earnings release: Q2 2026

Jul 31, 2026, 9:00 AM EDT - 4 weeks ago

AbbVie Earnings release: Q2 2026


AbbVie Quarterly report: Q2 2026

Jul 31, 2026, 9:00 AM EDT - 4 weeks ago

AbbVie Quarterly report: Q2 2026


AbbVie Reports Second-Quarter 2026 Financial Results

Jul 31, 2026, 7:47 AM EDT - 4 weeks ago

AbbVie Reports Second-Quarter 2026 Financial Results


JUVÉDERM® Day Returns to U.S. on August 19

Jul 30, 2026, 8:00 AM EDT - 4 weeks ago

JUVÉDERM® Day Returns to U.S. on August 19


AbbVie to Host Second-Quarter 2026 Earnings Conference Call

Jun 26, 2026, 8:00 AM EDT - 2 months ago

AbbVie to Host Second-Quarter 2026 Earnings Conference Call


AbbVie's $11 Billion Immunology Bet

Jun 24, 2026, 12:51 PM EDT - 2 months ago

AbbVie's $11 Billion Immunology Bet

APGE


AbbVie to Buy Apogee Therapeutics for $10.9 Billion

Jun 22, 2026, 10:15 AM EDT - 2 months ago

AbbVie to Buy Apogee Therapeutics for $10.9 Billion

APGE


AbbVie Transcript: M&A announcement

Jun 22, 2026, 9:00 AM EDT - 2 months ago

AbbVie Transcript: M&A announcement


AbbVie Slides: M&A announcement

Jun 22, 2026, 9:00 AM EDT - 2 months ago

AbbVie Slides: M&A announcement


AbbVie Press release: M&A announcement

Jun 22, 2026, 9:00 AM EDT - 2 months ago

AbbVie Press release: M&A announcement


AbbVie to Buy Apogee Therapeutics for $10.9 Billion in Cash

Jun 22, 2026, 7:42 AM EDT - 2 months ago

AbbVie to Buy Apogee Therapeutics for $10.9 Billion in Cash

APGE


AbbVie strikes $10.9 billion deal for Apogee Therapeutics

Jun 22, 2026, 7:04 AM EDT - 2 months ago

AbbVie strikes $10.9 billion deal for Apogee Therapeutics

APGE


AbbVie Declares Quarterly Dividend

Jun 18, 2026, 4:05 PM EDT - 2 months ago

AbbVie Declares Quarterly Dividend


Diviend__dollar
Diviend__dollar Aug. 31 at 9:29 PM
Investing $10,000 in EACH of these names would pay the following annual dividends $AVGO $70 $ABBV $270 $JNJ $202 $LLY $60 $SCHD $301 Here is the 5 Year Growth for each of these as well $AVGO 13% $ABBV 6% $JNJ 5% $LLY 15% $SCHD 8%
0 · Reply
p3akyblinder
p3akyblinder Aug. 31 at 8:56 PM
$MLTX Talk about perfect timing for my last post... the appointment of Liz Gutierrez as U.S. President was just announced on LinkedIn. "I'm thrilled to begin a new chapter as President, U.S. at MoonLake Immunotherapeutics. The opportunity to help build the U.S. organization at such an exciting point in the company's evolution is incredibly energizing. Since joining, I've been struck not only by the caliber of talent across the organization, but also by the culture. There is a strong sense of purpose, openness, and shared commitment to making a difference for patients that makes MoonLake a truly special place to be." MoonLake will be acquired and operated as a wholly-owned subsidiary of $LLY , $ABBV , $MRK, or $NVS . You heard it here first.
1 · Reply
LT_Smash
LT_Smash Aug. 31 at 7:56 PM
0 · Reply
Stocktwits
Stocktwits Aug. 31 at 7:40 PM
$ABBV chart courtesy of @JFDI
0 · Reply
ilcail
ilcail Aug. 31 at 7:20 PM
$SLS 009 (2nd drug) design to work in combo with approved Venetoclax from $ABBV. Ven is a BCL-2 inhibitor. A main escape hatch is MCL-1, which can be stared by CDK9 inhibition... by SLS009. Sellas’s thesis: aza/ven + SLS009 hits both anti-apoptotic arms.
2 · Reply
JFDI
JFDI Aug. 31 at 7:07 PM
$ABBV off the 10wk SMA
0 · Reply
nlrmandate
nlrmandate Aug. 31 at 6:06 PM
$VKTX Hey $ABBV $NVO $AZN ..... Viking is the ONLY clinical biotech with a pipeline capable of competing with $LLY within 12-18 months. Buy or partner with Viking NOW or be prepared for $LLY to own the freakin world in a few years!!
1 · Reply
WallStJesus
WallStJesus Aug. 31 at 6:04 PM
$ABBV REPEAT MARCH BUYER
0 · Reply
nlrmandate
nlrmandate Aug. 31 at 3:26 PM
$VKTX Hey $ABBV $NVO ..... Viking is the ONLY clinical biotech with a pipeline capable of competing with LLY within 18 months. BO or partner with Viking NOW or LLY will own the freakin world in a few years!!
0 · Reply
focafoca99
focafoca99 Aug. 31 at 3:12 PM
$ABBV set to appear at the Wells Fargo 21st Annual Healthcare Conference on Sep 9, 2026. https://www.rapidticker.com/news/abbv-abbvie-to-present-at-the-09b424
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Aug. 31 at 2:02 PM
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Aug. 31 at 1:00 PM
$SLS $MRK $MRNA $ABBV YOU NEVER HAVE A PROBLEM ENROLLING A TRIAL WHERE PATIENTS ARE DOING WELL...
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Aug. 31 at 12:43 PM
$SLS $MRK $MRNA its been 112 Days since the 78th event occurred. 3 months and 22 days. it had been 1 event per month for the prior 18 - from 60 to 78. • Dec 8 2024 60th Event -- • Jan 23 2025 -- Idmc unblinded actual P3 MOS and IR Data - SHARE PRICE LAUNCHED MOS data TOLD $ABBV $BMY dr's immediately knew it was Gps doing what its done in all 7 Prior Trials - and 80% Immune Response Rates Confirmed it -- GPS MOS in the P3 would be much longer than P2. • Dec 26th 2025 72nd Event - SHARE PRICE LAUNCHED 22.67 Days Per Event • May 11 2026 78th Event - Again the SHARE PRICE LAUNCHED ANY DAY NOW we WILL GET THE 80th EVENT PR and the Share Price will Launch
0 · Reply
Snipertradesexpert
Snipertradesexpert Aug. 31 at 8:35 AM
$ABBV GET READY FOR THIS ALSO🥂
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Aug. 31 at 8:02 AM
$SLS its been 112 Days since the 78th event occurred. 3 months and 22 days. it had been 1 event per month for the prior 18 - from 60 to 78. • Dec 8 2024 60th Event -- • Jan 23 2025 -- Idmc unblinded actual P3 MOS and IR Data - SHARE PRICE LAUNCHED MOS data TOLD $ABBV $BMY dr's immediately knew it was Gps doing what its done in all 7 Prior Trials - and 80% Immune Response Rates Confirmed it -- GPS MOS in the P3 would be much longer than P2. • Dec 26th 2025 72nd Event - SHARE PRICE LAUNCHED 22.67 Days Per Event • May 11 2026 78th Event - Again the SHARE PRICE LAUNCHED ANY DAY NOW we WILL GET THE 80th EVENT PR and the Share Price will Launch
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Aug. 31 at 6:02 AM
$SLS $MRK $MRNA $ABBV $SLS is worth $50B to big pharma the instant Gps Phase 3 results are announced - any day now. • Why Did the VIALE-M Phase 3 Trial for AML First Remission Patients Fail? • Why DID ABBV have difficulty ENROLLING PATIENTS in the AML Maintenance Trial? Why are We SEEING MIRACULOUS Survival in the SLS Phase 3 AML Remission Maintenance Trial - when BAT for CONTROL Patients FAILED 2 Phase 3 AML Remission Trials?
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Aug. 31 at 4:04 AM
$SLS $MRNA ANY DAY NOW we WILL GET THE 80th EVENT PR and the Share Price will Launch. - its been 111 Days since the 78th event occurred. it'd been 1 event per month for the prior 18 - from 60 to 78. • Dec 8 2024 60th Event -- • Jan 23 2025 -- Idmc unblinded actual P3 MOS and IR Data - SHARE PRICE LAUNCHED MOS data TOLD $ABBV $BMY dr's immediately knew it was Gps doing what its done in all 7 Prior Trials - and 80% Immune Response Rates Confirmed it -- GPS MOS in the P3 would be much longer than P2. • Dec 26th 2025 72nd Event - SHARE PRICE LAUNCHED 22.67 Days Per Event • May 11 2026 78th Event - Again the SHARE PRICE LAUNCHED ANY DAY NOW we WILL GET THE 80th EVENT PR and the Share Price will Launch
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Aug. 30 at 9:30 PM
$SLS $MRNA ANY DAY NOW we WILL GET THE 80th EVENT PR and the Share Price will Launch. - its been 111 Days since the 78th event occurred. it'd been 1 event per month for the prior 18 - from 60 to 78. • Dec 8 2024 60th Event -- • Jan 23 2025 -- Idmc unblinded actual P3 MOS and IR Data - SHARE PRICE LAUNCHED MOS data TOLD $ABBV $BMY dr's immediately knew it was Gps doing what its done in all 7 Prior Trials - and 80% Immune Response Rates Confirmed it -- GPS MOS in the P3 would be much longer than P2. • Dec 26th 2025 72nd Event - SHARE PRICE LAUNCHED 22.67 Days Per Event • May 11 2026 78th Event - Again the SHARE PRICE LAUNCHED ANY DAY NOW we WILL GET THE 80th EVENT PR and the Share Price will Launch
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Aug. 30 at 9:12 PM
$SLS $MRK $MRNA $ABBV Gps Immunotherapy has proven Effective in preventing relapse and extending survival IN EVERY PREVIOUS TRIAL -- Including 2 Phase 2 Trials for AML Remission Maintenance. *Phase 3 Trial Results Imminent. Oral Aza -Onureg is the SOC for AML Patients in First Remission - achieved a MOS of 24.7 Months. $ABBV Conducted the VIALE-M PH3 trial Combining Oral Az w Venetoclax - it FAILED. GPS MOS in this Same First Remission Setting Achieved PH2 MOS >67.6 Months. SOC: 24.7 --- GPs: > 67.6 Again Note the Key Gps Specific Immune Response. Onureg Ph3 and GPS P2 Patients were not Eligible for Transplant. 6.7% of the Onureg CR1 Patients Subsequently rec'd transplant.
0 · Reply
DidYouReadThis
DidYouReadThis Aug. 30 at 7:00 PM
What’s closest to your #preferred #tempo of #pharma or #biotech #commercials #ads #ad #commercial ? $ABBV $REGN $NVS $OTLK #HEALTHCARE
0 · Reply
Gebinator
Gebinator Aug. 29 at 3:08 PM
$SLS G' Morning Longs 🌞 Apologies for kinda botching last evening's poll -- my bad -- unfortunately, consuming too much wobbly juice did play into the matter ... 😣 While the poll 👇 list of choices is in alphabetical order, as @Dollarking has indicated, $ABBV shouldn't be counted out. Point well-taken, only thing is @Stocktwits allows only four choices. To meet this challenge, another new poll could later include $ABBV as a distinct choice (replacing $LLY) OR aggravated with $LLY - represented as the 'dark horse' choice candidates from previous poll. In the meantime, for what it's worth, do consider the current choices, as listed 👇 Of these four, which will it be?
2 · Reply
tr3ndo
tr3ndo Aug. 29 at 5:34 AM
$ABBV a seller zone formed, a local maximum was confirmed, and a downward correction is developing on the daily chart around $259. Price is reacting from the recent highs. AI Detective currently assigns a 47% probability to a local minimum being confirmed next. Waiting for price to confirm its next direction.
0 · Reply